Načítá se...
Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
BACKGROUND: Certolizumab pegol is used to treat ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, and rheumatoid arthritis. Unlike other monoclonal antibodies such as infliximab and adalimumab, certolizumab does not contain an Fc fraction and hence does not induce complement activation....
Uloženo v:
| Vydáno v: | Balkan Med J |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Galenos Publishing
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6158467/ https://ncbi.nlm.nih.gov/pubmed/29687787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/balkanmedj.2017.1224 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|